Maarten J van der Doelen1,2, Agnes Stockhaus3, Yuanjun Ma4, Niven Mehra5, Jeffrey Yachnin4,6, Winald R Gerritsen5, Sten Nilsson4,6, Inge M van Oort7, Anders Ullén4,6. 1. Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, The Netherlands. Maarten.vanderDoelen@radboudumc.nl. 2. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Maarten.vanderDoelen@radboudumc.nl. 3. Department of Oncology-Pathology, Mälarsjukhuset, Eskilstuna, Sweden. 4. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 5. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Karolinska University Hospital, Stockholm, Sweden. 7. Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, The Netherlands.
Abstract
PURPOSE: Radium-223 is a life-prolonging therapy for castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases. However, validated biomarkers for response monitoring are lacking. The study aim was to investigate whether early alkaline phosphatase (ALP) dynamics after the first radium-223 injection can act as surrogate marker for overall survival (OS). METHODS: This retrospective multicenter study included consecutive CRPC patients treated with radium-223. Patients were divided into four subgroups based on baseline ALP level (normal/elevated) and early ALP response, defined as ≥10% ALP decrease after the first radium-223 injection. Primary endpoint was OS among the subgroups. Secondary endpoints included time to first skeletal-related event, time to ALP progression, and treatment completion rate. RESULTS: A total of 180 patients were included for analysis. Median OS was 13.5 months (95% confidence interval 11.5-15.5). Patients with elevated baseline ALP without ALP response after the first injection had significantly worse OS when compared to all other patients (median OS 7.9 months versus 15.7 months, hazard ratio 2.56, 95% confidence interval 1.73-3.80, P < 0.001). Multivariate analysis demonstrated that elevated baseline ALP without ALP response after the first injection, the number of prior systemic therapies, baseline LDH level, and baseline ECOG performance status were prognostic factors of OS. Patients with elevated baseline ALP without ALP response after the first injection had significantly shorter times to ALP progression and first skeletal-related event, and more frequently discontinued radium-223 therapy when compared to other patients. CONCLUSION: Early treatment-induced changes in ALP after one radium-223 injection were associated with OS in metastatic CRPC patients.
PURPOSE:Radium-223 is a life-prolonging therapy for castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases. However, validated biomarkers for response monitoring are lacking. The study aim was to investigate whether early alkaline phosphatase (ALP) dynamics after the first radium-223 injection can act as surrogate marker for overall survival (OS). METHODS: This retrospective multicenter study included consecutive CRPC patients treated with radium-223. Patients were divided into four subgroups based on baseline ALP level (normal/elevated) and early ALP response, defined as ≥10% ALP decrease after the first radium-223 injection. Primary endpoint was OS among the subgroups. Secondary endpoints included time to first skeletal-related event, time to ALP progression, and treatment completion rate. RESULTS: A total of 180 patients were included for analysis. Median OS was 13.5 months (95% confidence interval 11.5-15.5). Patients with elevated baseline ALP without ALP response after the first injection had significantly worse OS when compared to all other patients (median OS 7.9 months versus 15.7 months, hazard ratio 2.56, 95% confidence interval 1.73-3.80, P < 0.001). Multivariate analysis demonstrated that elevated baseline ALP without ALP response after the first injection, the number of prior systemic therapies, baseline LDH level, and baseline ECOG performance status were prognostic factors of OS. Patients with elevated baseline ALP without ALP response after the first injection had significantly shorter times to ALP progression and first skeletal-related event, and more frequently discontinued radium-223 therapy when compared to other patients. CONCLUSION: Early treatment-induced changes in ALP after one radium-223 injection were associated with OS in metastatic CRPC patients.
Authors: Fred Saad; Joan Carles; Silke Gillessen; Axel Heidenreich; Daniel Heinrich; Jeremy Gratt; Jérémy Lévy; Kurt Miller; Sten Nilsson; Oana Petrenciuc; Marcello Tucci; Manfred Wirth; Judith Federhofer; Joe M O'Sullivan Journal: Lancet Oncol Date: 2016-07-26 Impact factor: 41.316
Authors: Janet E Brown; Richard J Cook; Pierre Major; Allan Lipton; Fred Saad; Matthew Smith; Ker-Ai Lee; Ming Zheng; Yong-Jiang Hei; Robert E Coleman Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor Journal: N Engl J Med Date: 2013-07-18 Impact factor: 91.245
Authors: O Sartor; R E Coleman; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; N J Vogelzang; Ø Bruland; S Kobina; S Wilhelm; L Xu; M Shan; M W Kattan; C Parker Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976
Authors: C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard Journal: Eur Urol Date: 2013-11-22 Impact factor: 20.096
Authors: Maarten J van der Doelen; Irma M Oving; Dirk N J Wyndaele; Jean-Paul van Basten; Frederiek Terheggen; Addy C M van de Luijtgaarden; Wim J G Oyen; W Dick van Schelven; Franchette van den Berkmortel; Niven Mehra; Marcel J R Janssen; Judith B Prins; Winald R Gerritsen; José A E Custers; Inge M van Oort Journal: Prostate Cancer Prostatic Dis Date: 2022-07-08 Impact factor: 5.554